28th May 2026 14:33
Nuformix PLC - London-based developer of treatments for fibrosis and oncology - Pretax loss narrows to GBP346,577 in the six months ended March 31, from GBP376,668 a year prior. Looking ahead, Nuformix says: "The company continues to advance and exploit the current assets within the portfolio through the research & development and business development activities as set out above. The strategy of the group is to continue to increase the value of its existing assets while maintaining tight control of costs, including conducting business development/licensing activities using a structured and data-driven approach, with the goal of seeking global licensing deals." Read More
